Loading
Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.
Jiangsu Aosaikang's limertinib (ASK120067) was approved by the NMPA in 2024 for locally advanced or metastatic EGFR T790M-positive non-small cell lung cancer after progression on earlier EGFR inhibitors, joining osimertinib, furmonertinib and befotertinib among China's third-generation options. A phase 3 first-line trial against gefitinib is registered.
A covalent inhibitor of EGFR sensitising and T790M resistance mutations that spares wild-type EGFR, the osimertinib class. Connects to EGFR.
1.Limertinib slips into a pocket on EGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Limertinib" OR ABSTRACT:"Limertinib" OR TITLE:"ASK120067" OR ABSTRACT:"ASK120067") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Limertinib, not a curated reading list.
Shares Aosaikang Pharmaceutical and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.